NEW YORK, Aug. 15 The Hereditary Disease Foundation (HDF)is extremely pleased the U.S. Food and Drug Administration has approvedXenazine, or tetrabenazine, for the treatment of chorea associated withHuntington's disease.
"Chorea is a major cause of disability and death in patients withHuntington's disease. Chorea is not just a mere inconvenience; it can preventHuntington's disease patients from walking, talking, working, watchingtelevision and almost every aspect of one's life. We are ecstatic that,through the approval of Xenazine, patients and families will have the optionto take the only drug developed specifically for treating the movements ofHuntington's disease," said Nancy Wexler, Ph.D., Higgins Professor ofNeuropsychology in the departments of neurology and psychiatry at ColumbiaUniversity and president of the Hereditary Disease Foundation.
"While we are still hopeful we can some day find a cure, the approval ofXenazine is a breakthrough for the Huntington's disease community," said Dr.Wexler.
The approval of Xenazine marks the first and only FDA-approved treatmentfor any symptom of Huntington's disease.
SOURCE Hereditary Disease Foundation